-1Image

Generic Name Brand Name Classific ation Indicatio n Action

Ciprofloxacin Cipro Fluoroquinolone. Anti-infective A fluoroquinolone that inhibits the enzyme DNA gyrase in susceptible bacteria, interfering with bacterial cell replication. Therapeutic Effect: Bactericidal. 500mg tab BID PO Hypersensitivity to ciprofloxacin or other quinolones; vaccinia, varicella, epithelial herpes simplex, keratitis, mycobacterial infection, fungal disease of ocular structure, use after uncomplicated removal of a foreign body. FREQUENT (5%U2%): Nausea, diarrhea, dyspepsia, vomiting, constipation, flatulence, confusion, crystalluria Superinfection (especially enterococcal or fungal), nephropathy, cardiopulmonary arrest, chest pain, and cerebral thrombosis may occur. Hypersensitivity reactions, including photosensitivity (as evidenced by rash, pruritus, blisters, edema, and burning skin), have occurred in patients receiving fluoroquinolones. Arthropathy may occur if the drug is given to children younger than 18 years. Sensitization to the ophthalmic form of the drug may contraindicate later systemic use of ciprofloxacin.

Dosage Contrain dication

Side effects Adverse effects

Nursing responsi bilities

BASELINE ASSESSMENT Question for history of hypersensitivity to ciprofloxacin, quinolones. INTERVENTION/EVALUATION Evaluate food tolerance. Determine pattern of bowel activity. Monitor for dizziness, headache, visual changes, tremors. Assess for chest, joint pain. Ophthalmic: Observe therapeutic response. PATIENT/FAMILY TEACHING Do not skip doses; take full course of therapy. N Take with 8 oz water; drink several glasses of water between meals. N Eat and drink high sources of ascorbic acid (cranberry juice, citrus fruits) to prevent crystalluria. N Do not take antacids (reduces/destroys effectiveness). N Shake suspension well before using; do not chew microcapsules in suspension. N Sugarless gum or hard candy may relieve bad taste. N Ophthalmic: Explain possibility of crystal precipitate forming, usual resolution in 1U7 days.

Source

Saunders Nursing Drug Handbook 2007, and 2008

Image

Generic Name Brand Name Classificatio n Indication

Paracetamol Perfalgan Analgesic, muscle relaxant Relief to mild moderate pain, treatment of fever

Action

Decreases fever by inhibiting the effects of pyrogens on the hypothalamic heat regulating centers and by a hypothalamic action leading to sweating and vasodilation. Relieves pain by inhibiting prostaglandin synthesis at the CNS but does not have anti-inflammatory action because of its minimal effect of peripheral prostaglandin synthesis. 600 mg IVTT then 300 mg IVTT q4 for T= 38 C Hypersensitivity; intolerance to tartazine (yellow dye #5), alcohol, table sugar, saccharine. Stimulation, drowsiness, nausea and vomiting, rash, cyanosis Hepatic seizure, renal failure, neutripenia, leucopenia, hemolytic anemia, Tell patient to read label on other OTC drugs advise patient to avoid taking more than one product containing paracetamol at one at a time. Advise patient to avoid alcohol, acute poisoning with liver damage may result, acute toxicity includes symptoms of nausea, vomiting and abdominal pain. Teach patient to recognize signs of chronic overdose, malise, fever, sore throat. Inform patient that urine may become dark brown as result of phenecetin.

Dosage Contraindica tion Side effects Adverse effects Nursing responsibiliti es

Source

Drug Guide for Nurses Daviss

Image

Generic Name Brand Name Classificatio n Indication

Etericoxib ARCOXIA COX-2 inhibitor, non-steroidal antiinflammatory and antirheumatic products, coxibs. This medication is a non-steroidal anti-inflammatory drug (NSAID), prescribed for osteoarthritis, rheumatoid arthritis and gouty arthritis.

Action Dosage Contraindica tion Side effects 120 mg tab OD for pain Contraindicated in patients with peptic ulcer, severe heart disease, stroke, and hypersensitivity. Central Nervous System - Headache, dizziness, nervousness, depression, drowsiness, insomnia, vertigo and ringing in the ear. Heart - Chest pain, high blood pressure and fluid retention. Metabolic - Taste disturbances, mouth ulcer, loss of appetite and weight loss. Miscellaneous - Kidney damage, fever, GI disorders, muscle pain and influenza-like syndrome. GI disorders; ischemic cardiac events; hypersensitivity reactions, headache, dizziness, nervousness, depression, drowsiness, insomnia, vertigo, tinnitus, photosensitivity; blood disorders, fluid retention, hypertension; dry mouth, taste disturbance, mouth ulcers; appetite and wt changes; chest pain, fatigue, paraesthesia, influenza-like syndrome, myalgia. Renal toxicity.

Adverse effects

Nursing responsibiliti es

Assessment Before administering Celebrex, nurses must assess patients for any contraindications (factors or symptoms that indicate a treatment is not advised). Contraindications for the use of Celebrex include pregnancy, asthma and hypersensitivity to aspirin, iodides, other NSAIDs and sulfonamides. Celebrex is also contraindicated for the treatment of pain immediately before and after coronary artery bypass graft surgery. Celebrex can cause several serious side effects including heart attack, stroke, high blood pressure, kidney failure, bleeding, anemia, liver failure and allergic reactions. Other side effects include stomach pain, constipation, diarrhea, gas, heartburn, nausea, vomiting and dizziness. Nurses should be aware of these side effects and should regularly assess for signs and symptoms of these conditions in patients undergoing Celebrex therapy. Administration Nurses must teach patients how to take Celebrex properly. In addition, they also must alert patients to the potential side effects of the drug. Celebrex should be taken with food or milk to lessen the chance of gastric upset. Patients should be taught never to crush, dissolve or chew this medication and to never exceed the prescribed dose as deaths have occurred. Patients also should be taught to discontinue Celebrex use and contact their physician if they have any gastrointestinal symptoms such as bloody stools or cramping. Bleeding, fatigue or bruising also should be reported. Patients experiencing difficulty breathing, chest pain, slurred speech or partial paralysis should seek immediate emergency assistance. Celebrex is often discontinued before surgery. Therefore patients should consult their physician before undergoing any surgical procedures. Evaluation Patients undergoing therapy with Celebrex should be evaluated on an ongoing basis to determine the efficacy of treatment. Signs that a patient is responding properly to treatment include decreased pain and inflammation. During the evaluation process, patients also should be assessed for side effects. If side effects are present, the patient's physician should be notified to determine if the benefits of treatment outweigh the symptoms or risks involved.

Read more: Nursing Responsibilities in Administering Celebrex | eHow.com http://www.ehow.com/list_6776858_nursing-responsibilities-administeringcelebrex.html#ixzz1ts3KL4YP

Source

http://www.medindia.net/doctors/drug_information/etoricoxib.htm#ixzz1t rzhaA2d